Vault and malignant endocrine neoplasm: Accordingly, our study clearly identifies vault RNA1-1 as a highly interesting therapeutic biomarker for endocrine tumors independent of tumor type and therapy but dependent on specific responsiveness, which could be, due to the detected exosomal release of vault RNAs, furthermore isolated from patients’ bodily fluids.